These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30025814)

  • 1. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
    Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
    Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
    Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4(Lys
    Hasib A; Ng MT; Tanday N; Craig SL; Gault VA; Flatt PR; Irwin N
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3106. PubMed ID: 30499633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
    Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
    Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
    Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
    Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.
    Martin CM; Parthsarathy V; Hasib A; Ng MT; McClean S; Flatt PR; Gault VA; Irwin N
    PLoS One; 2016; 11(3):e0152818. PubMed ID: 27032106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
    Irwin N; Pathak V; Flatt PR
    Diabetes; 2015 Aug; 64(8):2996-3009. PubMed ID: 25883113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
    Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
    Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of the biological activity of xenin-25 degradation fragment peptides.
    Martin CM; Parthsarathy V; Pathak V; Gault VA; Flatt PR; Irwin N
    J Endocrinol; 2014 May; 221(2):193-200. PubMed ID: 24520141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
    Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
    Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.
    Gault VA; Martin CM; Flatt PR; Parthsarathy V; Irwin N
    Acta Diabetol; 2015 Jun; 52(3):461-71. PubMed ID: 25374384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism.
    Craig SL; Gault VA; McClean S; Hamscher G; Irwin N
    Mol Cell Endocrinol; 2019 Oct; 496():110523. PubMed ID: 31352038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
    Irwin N; Hunter K; Frizzell N; Flatt PR
    Regul Pept; 2009 Feb; 153(1-3):70-6. PubMed ID: 19073224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.